Tsereton - instructions for use, dose, side effects, contraindications

Composition:1 ampoule (4 ml) contains as an active substance choline alfoscerate polyhydrate (in terms of anhydrous choline alphoscerate) - 1000 mg, excipients: water for injection - up to 4 ml.

Description:Transparent colorless liquid.

Pharmacotherapeutic group:Nootropic agent.

ATX: & nbsp

N.07.A.X.02 Choline alfoscerate

Pharmacodynamics:Nootropic agent. Central cholinostimulator, which contains 40.5% of metabolically protected choline. Metabolic protection contributes to the release of choline in the brain. Provides the synthesis of acetylcholine and phosphatidylcholine in neuronal membranes, improves blood flow and enhances metabolic processes in the central nervous system, activates the reticular formation. Increases the linear velocity of blood flow on the side of traumatic brain injury, promotes normalization of spatiotemporal characteristics of spontaneous bioelectrical activity of the brain,regress of focal neurological symptoms and restoration of consciousness; has a positive effect on the cognitive and behavioral responses of patients with cerebral vascular diseases (discirculatory encephalopathy and residual phenomena of cerebral circulation disorders). Provides a preventive and corrective effect on the pathogenetic factors of the involutionary psychoorganic syndrome, changes the phospholipid composition of neuronal membranes and reduces cholinergic activity. Stimulates the dose-dependent release of acetylcholine under physiological conditions; participating in the synthesis of phosphatidylcholine (membrane phospholipid), improves synaptic transmission, plasticity of neuronal membranes, receptor function. Not

has an effect on the reproductive cycle and does not have a teratogenic, mutagenic effect.

Pharmacokinetics:

Easily penetrates the blood-brain barrier, 85% is excreted by the lungs in the form of carbon dioxide, the rest (15%) is excreted by the kidneys and through the intestine.

Indications:

- acute and recovery periods of severe craniocerebral trauma and ischemic stroke, the recovery period of hemorrhagic stroke,flowing with focal hemispheric symptoms or symptoms of damage to the brainstem;

- psycho-organic syndrome in the background of degenerative and involuntary changes in the brain;

- Cognitive disorders (impaired mental function, memory, confusion, consciousness, disorientation, decreased motivation, initiative and ability to concentrate), including with dementia and encephalopathy;

- senile pseudo-melancholy.

Contraindications:

- hypersensitivity to the drug or its components;

- hemorrhagic stroke (acute stage);

- children's age till 18 years;

- pregnancy;

- the period of breastfeeding.

Pregnancy and lactation:The use of the drug Tsereton ® during pregnancy and during breastfeeding is contraindicated. For the duration of treatment with the drug Tsereton ®, breast-feeding should be discontinued.

Dosing and Administration:When acute conditions are administered intravenously (slowly) or deep, intramuscularly (slowly) at 1000 mg (1 ampoule) per day for 10-15 days.

Side effects:

From the digestive system: constipation, diarrhea, dryness of the oral mucosa, pharyngitis.

From the nervous system: headache, drowsiness, insomnia, aggressiveness, anxiety, nervousness, cerebral ischemia, convulsions, dizziness.

From the skin: rash, hives.

Other: pain in the injection site, frequency of urination.

Allergic reactions.

Perhaps the appearance of nausea (mainly as a consequence of dopaminergic activation), in this case, reduce the dose of the drug.

Overdose:Nausea may occur. Treatment: symptomatic therapy.

Interaction:Significant interaction with other drugs has not been identified.

Special instructions:Tsereton ® does not affect the speed of psychomotor reactions.

Effect on the ability to drive transp. cf. and fur:Tsereton® does not affect the ability to drive vehicles and mechanisms.

Form release / dosage:Solution for intravenous and intramuscular injection 250 mg / ml.

Packaging:

To 4 ml in ampoules of colorless neutral glass type 1 with a color fracture ring or with a colored dot and a notch. One, two or three color rings and / or a two-dimensional bar code, and / or alphanumeric coding or without additional color rings, a two-dimensional bar code, and an alphanumeric collation are additionally applied to the ampoules. By 3 or 5 ampoules in the outline of the cell.

For 1 or 2 contour mesh packages together with instructions for use in a pack of cardboard.

Storage conditions:Store in a dark place at a temperature of no higher than 25 ° C. Keep out of the reach of children.

Shelf life:5 years. Do not use after expiry date.

Terms of leave from pharmacies:On prescription

Registration number:LS-002652

Date of registration:21.09.2011

The owner of the registration certificate:FarmSirma Soteks, ZAO FarmSirma Soteks, ZAO Russia

Manufacturer: & nbsp

FarmSirma Soteks, ZAO Russia

Information update date: & nbsp26.09.2015

Illustrated instructions

Instructions

Cereton® (Cereton®)